ClinicalTrials.gg
CompletedNCT00454649Updated Apr 4, 2012Results posted

Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor

A Phase 1 interventional study of Axitinib + Paclitaxel + Carboplatin (Cohort 1) and Axitinib + Paclitaxel + Carboplatin (Cohort 2) in Neoplasms, sponsored by Pfizer. Completed at 13 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-04.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
102
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

To determine the best dose of this investigational agent AG-013736 in combination with various standard of care treatments for advanced solid tumors.

02

Conditions studied

  • Neoplasms

Browse trials for

Keywords

  • axitinib
  • chemotherapy
  • anti-angiogenesis
  • VEGF inhibition
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 102 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Advanced solid tumors suitable for treatment with Taxanes, with or without carboplatin, or treatment with Capecitabine, Gemcitabine/Cisplatin. or Pemetrexed/Cisplatin

Exclusion criteria

Exclusion Criteria:

  • Tumors abutting or providing support for blood vessels
  • Any significant gastrointestinal abnormalities or active bleeding.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Axitinib [AG-013736] + chemotherapy combination

    The following separate groups were included: axitinib 1. plus carboplatin/paclitaxel in three different schedules 2. plus paclitaxel 3. plus docetaxel/carboplatin 4. plus docetaxel 5. plus capecitabine 6. plus gemcitabine/cisplatin 7. plus pemetrexed/cisplatin

    Drug: Axitinib + Paclitaxel + Carboplatin (Cohort 1) · Drug: Axitinib + Paclitaxel + Carboplatin (Cohort 2) · Drug: Axitinib + Paclitaxel + Carboplatin (Cohort 3) · Drug: Axitinib + Paclitaxel (Cohort 4) · Drug: Axitinib + Docetaxel + Carboplatin (Cohort 4a) · Drug: Axitinib + Docetaxel (Cohort 5) · Drug: Axitinib + Capecitabine (Cohort 6) · Drug: Axitinib + Capecitabine (Cohort 7) · Drug: Axitinib + Gemcitabine + Cisplatin (Cohort 8) · Drug: Axitinib + Pemetrexed + Cisplatin (Cohort 9)

Interventions

  • DrugAxitinib + Paclitaxel + Carboplatin (Cohort 1)

    Drug pages: Axitinib · Paclitaxel · Carboplatin

    Axitinib (AG-013736) 1 milligram (mg) tablet orally twice daily (BID) as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel \[200 milligram/square meter (mg/m\^2)\] 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target area under the concentration-time curve (AUC) of 6.0 milligram\*minute/milliliter (mg\*min/mL) on Day 1 of Cycle 1 and all subsequent cycles.

  • DrugAxitinib + Paclitaxel + Carboplatin (Cohort 2)

    Drug pages: Axitinib · Paclitaxel · Carboplatin

    Axitinib (AG-013736) 3 tablets of 1 mg orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel (200 mg/m\^2) 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg\*min/mL on Day 1 of Cycle 1 and all subsequent cycles.

  • DrugAxitinib + Paclitaxel + Carboplatin (Cohort 3)

    Drug pages: Axitinib · Paclitaxel · Carboplatin

    Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel (200 mg/m\^2) 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg\*min/mL on Day 1 of Cycle 1 and all subsequent cycles.

  • DrugAxitinib + Paclitaxel (Cohort 4)

    Drug pages: Axitinib · Paclitaxel

    Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 25 of Cycle 1 (28 days) and then without interruption from Day 3 for Cycle 2 (28 days) and all subsequent cycles (28 days). Paclitaxel (90 mg/m\^2) 60-minute infusion on Day 1, 8, and 15 of each cycle.

  • DrugAxitinib + Docetaxel + Carboplatin (Cohort 4a)

    Drug pages: Axitinib · Docetaxel · Carboplatin

    Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Docetaxel (75 mg/m\^2) 60-minute infusion on Day 1 of every cycle. Carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg\*min/mL on Day 1 of Cycle 1 and all subsequent cycles.

  • DrugAxitinib + Docetaxel (Cohort 5)

    Drug pages: Axitinib · Docetaxel

    Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1. Axitinib (AG-013736) 5 mg oral tablet BID administered from Day 3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Docetaxel (100 mg/m\^2) 60-minute infusion on Day 1 of each cycle.

  • DrugAxitinib + Capecitabine (Cohort 6)

    Drug pages: Axitinib · Capecitabine

    Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1000 mg/m\^2) orally BID from Day 1 to Day 14 of each cycle.

  • DrugAxitinib + Capecitabine (Cohort 7)

    Drug pages: Axitinib · Capecitabine

    Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1250 mg/m\^2) orally BID from Day 1 to Day 14 of each cycle.

  • DrugAxitinib + Gemcitabine + Cisplatin (Cohort 8)

    Drug pages: Axitinib · Gemcitabine · Cisplatin

    Axitinib (AG-013736) 5 mg tablet orally BID from Day -5, -4 or -3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Gemcitabine (1250 mg/m\^2) 30-minute infusion on Day 1 and Day 8 of Cycle 1 and all subsequent cycles followed by cisplatin (80 mg/m\^2) infusion on Day 1 of each cycle.

  • DrugAxitinib + Pemetrexed + Cisplatin (Cohort 9)

    Drug pages: Axitinib · Pemetrexed · Cisplatin

    Axitinib (AG-013736) 5 mg tablet orally BID from Day -5, -4 or -3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Pemetrexed (500 mg/m\^2) 10-minute infusion followed by cisplatin (75 mg/m\^2) infusion on Day 1 of each cycle.

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) of Axitinib (AG-013736) in Combination With Chemotherapy

    MTD defined as the dose level at which more than 1 out of 6 participants experienced a dose limiting toxicity (DLT). DLT included grade (Gr) 4 neutropenia or thrombocytopenia, greater than or equal to (\>=) Gr 3 nonhematological toxicities or \>=0.5 teaspoon/day hemoptysis or \>=2 gram /24 hours proteinuria or inability to resume background chemotherapy or axitinib (AG-013736) dosing within 14 days of stopping due to treatment related toxicity.

    Time frame: Baseline to withdrawal from study or Day 21 of Cycle 1 [all cohorts except cohort 4 (Day 28 of Cycle 1)]

Secondary outcomes

  1. Area Under the Curve From Time Zero to Time 24 Hours [AUC (0-24)] for Axitinib (AG-013736)

    AUC (0-24) = Area under the plasma concentration versus time curve from time zero (pre-dose) to time 24 hours (0-24).

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 hr post-dose on Day -1 for cohort 1, 2, 3, 5 and 8; on Day 22 of Cycle 1 for cohort 4; on Day 18 of Cycle 1 for cohorts 6 and 7; 0 (pre-dose), 1.2, 2.2, 3.2, 4.2, 6.2, 8.2 hr post-dose on Day -1 for cohort 9

  2. Maximum Observed Plasma Concentration (Cmax) for Axitinib (AG-013736)

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 hr post-dose on Day -1 for cohort 1, 2, 3, 5 and 8; on Day 22 of Cycle 1 for cohort 4; on Day 18 of Cycle 1 for cohorts 6 and 7; 0 (pre-dose), 1.2, 2.2, 3.2, 4.2, 6.2, 8.2 hr post-dose on Day -1 for cohort 9

  3. Minimum Observed Plasma Trough Concentration (Cmin) for Axitinib (AG-013736)

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 hr post-dose on Day -1 for cohort 1, 2, 3, 5 and 8; on Day 22 of Cycle 1 for cohort 4; on Day 18 of Cycle 1 for cohorts 6 and 7; 0 (pre-dose), 1.2, 2.2, 3.2, 4.2, 6.2, 8.2 hr post-dose on Day -1 for cohort 9

  4. Apparent Oral Clearance (CL/F) for Axitinib (AG-013736)

    Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes and F is the absolute oral bioavailability. Apparent oral clearance(CL/F) is obtained following oral administration.

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 hr post-dose on Day -1 for cohort 1, 2, 3, 5 and 8; on Day 22 of Cycle 1 for cohort 4; on Day 18 of Cycle 1 for cohorts 6 and 7; 0 (pre-dose), 1.2, 2.2, 3.2, 4.2, 6.2, 8.2 hr post-dose on Day -1 for cohort 9

  5. Plasma Decay Half Life (t1/2) for Axitinib (AG-013736)

    t1/2 is the time measured for the plasma concentration to decrease by one half.

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 hr post-dose on Day -1 for cohort 1, 2, 3, 5 and 8; on Day 22 of Cycle 1 for cohort 4; on Day 18 of Cycle 1 for cohorts 6 and 7; 0 (pre-dose), 1.2, 2.2, 3.2, 4.2, 6.2, 8.2 hr post-dose on Day -1 for cohort 9

  6. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Paclitaxel

    AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).

    Time frame: 0 (pre-dose), 1, 2, 3, 3.25, 3.5, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3; 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 4

  7. Maximum Observed Plasma Concentration (Cmax) for Paclitaxel

    Time frame: 0 (pre-dose), 1, 2, 3, 3.25, 3.5, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3; 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 4

  8. Minimum Observed Plasma Trough Concentration (Cmin) for Paclitaxel

    Time frame: 0 (pre-dose), 1, 2, 3, 3.25, 3.5, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3; 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 4

  9. Plasma Clearance (CL) for Paclitaxel

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the plasma.

    Time frame: 0 (pre-dose), 1, 2, 3, 3.25, 3.5, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3; 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 4

  10. Plasma Decay Half Life (t1/2) for Paclitaxel

    t1/2 is the time measured for the plasma concentration to decrease by one half.

    Time frame: 0 (pre-dose), 1, 2, 3, 3.25, 3.5, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3; 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 4

  11. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Docetaxel

    AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 5

  12. Maximum Observed Plasma Concentration (Cmax) for Docetaxel

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 5

  13. Minimum Observed Plasma Trough Concentration (Cmin) for Docetaxel

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 5

  14. Plasma Clearance (CL) for Docetaxel

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the plasma.

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 5

  15. Plasma Decay Half Life (t1/2) for Docetaxel

    t1/2 is the time measured for the plasma concentration to decrease by one half.

    Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 5

  16. Area Under the Curve From Time Zero to Time 24 Hours [AUC (0-24)] for Capecitabine

    AUC (0-24) = Area under the plasma concentration versus time curve from time zero (pre-dose) to time 24 hours (0-24).

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hr post-dose on Day 1 of Cycle 2 for cohort 6 and 7

  17. Maximum Observed Plasma Concentration (Cmax) for Capecitabine

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hr post-dose on Day 1 of Cycle 2 for cohort 6 and 7

  18. Minimum Observed Plasma Trough Concentration (Cmin) for Capecitabine

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hr post-dose on Day 1 of Cycle 2 for cohort 6 and 7

  19. Apparent Oral Clearance (CL/F) for Capecitabine

    Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes and F is the absolute oral bioavailability. Apparent oral clearance(CL/F) is obtained following oral administration.

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hr post-dose on Day 1 of Cycle 2 for cohort 6 and 7

  20. Plasma Decay Half Life (t1/2) for Capecitabine

    t1/2 is the time measured for the plasma concentration to decrease by one half.

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hr post-dose on Day 1 of Cycle 2 for cohort 6 and 7

  21. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Gemcitabine

    AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).

    Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4 hr after start of infusion on Day 1 of Cycle 2 for cohort 8

  22. Maximum Observed Plasma Concentration (Cmax) for Gemcitabine

    Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4 hr after start of infusion on Day 1 of Cycle 2 for cohort 8

  23. Minimum Observed Plasma Trough Concentration (Cmin) for Gemcitabine

    Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4 hr after start of infusion on Day 1 of Cycle 2 for cohort 8

  24. Plasma Clearance (CL) for Gemcitabine

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the plasma.

    Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4 hr after start of infusion on Day 1 of Cycle 2 for cohort 8

  25. Plasma Decay Half Life (t1/2) for Gemcitabine

    t1/2 is the time measured for the plasma concentration to decrease by one half.

    Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4 hr after start of infusion on Day 1 of Cycle 2 for cohort 8

  26. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Carboplatin

    AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 5 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3

  27. Maximum Observed Plasma Concentration (Cmax) for Carboplatin

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 5 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3

  28. Minimum Observed Plasma Trough Concentration (Cmin) for Carboplatin

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 5 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3

  29. Plasma Clearance (CL) for Carboplatin

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the plasma.

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 5 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3

  30. Plasma Decay Half Life (t1/2) for Carboplatin

    t1/2 is the time measured for the plasma concentration to decrease by one half.

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 5 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3

  31. Area Under the Curve From Time Zero to Time 8 Hours [AUC (0-8)] for Cisplatin

    AUC (0-8) = Area under the plasma concentration versus time curve from time zero (pre-dose) to time 8 hours (0-8).

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 5, 7 hr after start of infusion on Day 1 of Cycle 2 for cohort 8 and 9

  32. Maximum Observed Plasma Concentration (Cmax) for Cisplatin

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 5, 7 hr after start of infusion on Day 1 of Cycle 2 for cohort 8 and 9

  33. Minimum Observed Plasma Trough Concentration (Cmin) for Cisplatin

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 5, 7 hr after start of infusion on Day 1 of Cycle 2 for cohort 8 and 9

  34. Plasma Clearance (CL) for Cisplatin

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the plasma.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 5, 7 hr after start of infusion on Day 1 of Cycle 2 for cohort 8 and 9

  35. Plasma Decay Half Life (t1/2) for Cisplatin

    t1/2 is the time measured for the plasma concentration to decrease by one half.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 5, 7 hr after start of infusion on Day 1 of Cycle 2 for cohort 8 and 9

  36. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Pemetrexed

    AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).

    Time frame: 0 (pre-dose), 10 minutes (end of infusion), 0.5, 1, 1.5, 2, 4, 6, 8 hr after end of infusion on Day 1 of Cycle 2 for cohort 9

  37. Maximum Observed Plasma Concentration (Cmax) for Pemetrexed

    Time frame: 0 (pre-dose), 10 minutes (end of infusion), 0.5, 1, 1.5, 2, 4, 6, 8 hr after end of infusion on Day 1 of Cycle 2 for cohort 9

  38. Minimum Observed Plasma Trough Concentration (Cmin) for Pemetrexed

    Time frame: 0 (pre-dose), 10 minutes (end of infusion), 0.5, 1, 1.5, 2, 4, 6, 8 hr after end of infusion on Day 1 of Cycle 2 for cohort 9

  39. Plasma Clearance (CL) for Pemetrexed

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the plasma.

    Time frame: 0 (pre-dose), 10 minutes (end of infusion), 0.5, 1, 1.5, 2, 4, 6, 8 hr after end of infusion on Day 1 of Cycle 2 for cohort 9

  40. Plasma Decay Half Life (t1/2) for Pemetrexed

    t1/2 is the time measured for the plasma concentration to decrease by one half.

    Time frame: 0 (pre-dose), 10 minutes (end of infusion), 0.5, 1, 1.5, 2, 4, 6, 8 hr after end of infusion on Day 1 of Cycle 2 for cohort 9

  41. Percentage of Participants With Objective Response

    Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0. Confirmed response are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

    Time frame: Baseline and thereafter every 2 cycles up to disease progression or discontinuation from study or up to 155 weeks

07

Results

Posted Mar 27, 2012

Participant flow

Participant flow — Overall Study
MilestoneAxitinib + Paclitaxel + Carboplatin (Cohort 1)Axitinib + Paclitaxel + Carboplatin (Cohort 2)Axitinib + Paclitaxel + Carboplatin (Cohort 3)Axitinib + Paclitaxel (Cohort 4)Axitinib + Docetaxel + Carboplatin (Cohort 4a)Axitinib + Docetaxel (Cohort 5)Axitinib + Capecitabine (Cohort 6)Axitinib + Capecitabine (Cohort 7)Axitinib + Gemcitabine + Cisplatin (Cohort 8)Axitinib + Pemetrexed + Cisplatin (Cohort 9)
Started3520717919216
Completed0111000011
Not completed3419617919205
Withdrew: Lack of efficacy2210304513102
Withdrew: Adverse event0130123462
Withdrew: Lost to follow-up0010001000
Withdrew: Other1153000031
Withdrew: Withdrawal by subject0000010210

Outcome measures

PrimaryMaximum Tolerated Dose (MTD) of Axitinib (AG-013736) in Combination With Chemotherapy

MTD defined as the dose level at which more than 1 out of 6 participants experienced a dose limiting toxicity (DLT). DLT included grade (Gr) 4 neutropenia or thrombocytopenia, greater than or equal to (\>=) Gr 3 nonhematological toxicities or \>=0.5 teaspoon/day hemoptysis or \>=2 gram /24 hours proteinuria or inability to resume background chemotherapy or axitinib (AG-013736) dosing within 14 days of stopping due to treatment related toxicity.

Time frame:
Baseline to withdrawal from study or Day 21 of Cycle 1 [all cohorts except cohort 4 (Day 28 of Cycle 1)]
Reported as:
Number · mg BID
Maximum Tolerated Dose (MTD) of Axitinib (AG-013736) in Combination With Chemotherapy
mg BIDAxitinib + Paclitaxel + Carboplatin (Cohort 1)Axitinib + Paclitaxel + Carboplatin (Cohort 2)Axitinib + Paclitaxel + Carboplatin (Cohort 3)Axitinib + Paclitaxel (Cohort 4)Axitinib + Docetaxel (Cohort 5)Axitinib + Capecitabine (Cohort 6)Axitinib + Capecitabine (Cohort 7)Axitinib + Gemcitabine + Cisplatin (Cohort 8)Axitinib + Pemetrexed + Cisplatin (Cohort 9)
Maximum Tolerated Dose (MTD) of Axitinib (AG-013736) in Combination With Chemotherapy5555NA5555
SecondaryArea Under the Curve From Time Zero to Time 24 Hours [AUC (0-24)] for Axitinib (AG-013736)

AUC (0-24) = Area under the plasma concentration versus time curve from time zero (pre-dose) to time 24 hours (0-24).

Time frame:
0 (pre-dose), 1, 2, 3, 4, 6, 8 hr post-dose on Day -1 for cohort 1, 2, 3, 5 and 8; on Day 22 of Cycle 1 for cohort 4; on Day 18 of Cycle 1 for cohorts 6 and 7; 0 (pre-dose), 1.2, 2.2, 3.2, 4.2, 6.2, 8.2 hr post-dose on Day -1 for cohort 9
Reported as:
Mean · nanogram*hour/milliliter (ng*hr/mL)
Area Under the Curve From Time Zero to Time 24 Hours [AUC (0-24)] for Axitinib (AG-013736)
nanogram*hour/milliliter (ng*hr/mL)Axitinib + Paclitaxel + Carboplatin (Cohort 1)Axitinib + Paclitaxel + Carboplatin (Cohort 2)Axitinib + Paclitaxel + Carboplatin (Cohort 3)Axitinib + Paclitaxel (Cohort 4)Axitinib + Docetaxel (Cohort 5)Axitinib + Capecitabine (Cohort 6)Axitinib + Capecitabine (Cohort 7)Axitinib + Gemcitabine + Cisplatin (Cohort 8)Axitinib + Pemetrexed + Cisplatin (Cohort 9)
Area Under the Curve From Time Zero to Time 24 Hours [AUC (0-24)] for Axitinib (AG-013736)61.58 ± 54.66242.41 ± 132.24475.18 ± 380.13154.43 ± 28.93780.99 ± 535.30365.95 ± 143.13449.99 ± 323.59416.30 ± 450.43420.64 ± 200.32
SecondaryMaximum Observed Plasma Concentration (Cmax) for Axitinib (AG-013736)
Time frame:
0 (pre-dose), 1, 2, 3, 4, 6, 8 hr post-dose on Day -1 for cohort 1, 2, 3, 5 and 8; on Day 22 of Cycle 1 for cohort 4; on Day 18 of Cycle 1 for cohorts 6 and 7; 0 (pre-dose), 1.2, 2.2, 3.2, 4.2, 6.2, 8.2 hr post-dose on Day -1 for cohort 9
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) for Axitinib (AG-013736)
ng/mLAxitinib + Paclitaxel + Carboplatin (Cohort 1)Axitinib + Paclitaxel + Carboplatin (Cohort 2)Axitinib + Paclitaxel + Carboplatin (Cohort 3)Axitinib + Paclitaxel (Cohort 4)Axitinib + Docetaxel (Cohort 5)Axitinib + Capecitabine (Cohort 6)Axitinib + Capecitabine (Cohort 7)Axitinib + Gemcitabine + Cisplatin (Cohort 8)Axitinib + Pemetrexed + Cisplatin (Cohort 9)
Maximum Observed Plasma Concentration (Cmax) for Axitinib (AG-013736)5.97 ± 2.5923.36 ± 8.0842.58 ± 18.2544.58 ± 44.7867.96 ± 39.2437.51 ± 15.3143.97 ± 28.8240.97 ± 33.0631.53 ± 22.87
SecondaryMinimum Observed Plasma Trough Concentration (Cmin) for Axitinib (AG-013736)
Time frame:
0 (pre-dose), 1, 2, 3, 4, 6, 8 hr post-dose on Day -1 for cohort 1, 2, 3, 5 and 8; on Day 22 of Cycle 1 for cohort 4; on Day 18 of Cycle 1 for cohorts 6 and 7; 0 (pre-dose), 1.2, 2.2, 3.2, 4.2, 6.2, 8.2 hr post-dose on Day -1 for cohort 9
Reported as:
Mean · ng/mL

No measurements were reported for this outcome.

SecondaryApparent Oral Clearance (CL/F) for Axitinib (AG-013736)

Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes and F is the absolute oral bioavailability. Apparent oral clearance(CL/F) is obtained following oral administration.

Time frame:
0 (pre-dose), 1, 2, 3, 4, 6, 8 hr post-dose on Day -1 for cohort 1, 2, 3, 5 and 8; on Day 22 of Cycle 1 for cohort 4; on Day 18 of Cycle 1 for cohorts 6 and 7; 0 (pre-dose), 1.2, 2.2, 3.2, 4.2, 6.2, 8.2 hr post-dose on Day -1 for cohort 9
Reported as:
Mean · Liter/hour (L/hr)
Apparent Oral Clearance (CL/F) for Axitinib (AG-013736)
Liter/hour (L/hr)Axitinib + Paclitaxel + Carboplatin (Cohort 1)Axitinib + Paclitaxel + Carboplatin (Cohort 2)Axitinib + Paclitaxel + Carboplatin (Cohort 3)Axitinib + Paclitaxel (Cohort 4)Axitinib + Docetaxel (Cohort 5)Axitinib + Capecitabine (Cohort 6)Axitinib + Capecitabine (Cohort 7)Axitinib + Gemcitabine + Cisplatin (Cohort 8)Axitinib + Pemetrexed + Cisplatin (Cohort 9)
Apparent Oral Clearance (CL/F) for Axitinib (AG-013736)49.39 ± 34.4640.72 ± 46.7529.73 ± 18.4965.69 ± 11.9414.35 ± 7.6726.64 ± 15.5883.46 ± 171.0550.05 ± 56.7525.10 ± 21.31
SecondaryPlasma Decay Half Life (t1/2) for Axitinib (AG-013736)

t1/2 is the time measured for the plasma concentration to decrease by one half.

Time frame:
0 (pre-dose), 1, 2, 3, 4, 6, 8 hr post-dose on Day -1 for cohort 1, 2, 3, 5 and 8; on Day 22 of Cycle 1 for cohort 4; on Day 18 of Cycle 1 for cohorts 6 and 7; 0 (pre-dose), 1.2, 2.2, 3.2, 4.2, 6.2, 8.2 hr post-dose on Day -1 for cohort 9
Reported as:
Mean · hr
Plasma Decay Half Life (t1/2) for Axitinib (AG-013736)
hrAxitinib + Paclitaxel + Carboplatin (Cohort 1)Axitinib + Paclitaxel + Carboplatin (Cohort 2)Axitinib + Paclitaxel + Carboplatin (Cohort 3)Axitinib + Paclitaxel (Cohort 4)Axitinib + Docetaxel (Cohort 5)Axitinib + Capecitabine (Cohort 6)Axitinib + Capecitabine (Cohort 7)Axitinib + Gemcitabine + Cisplatin (Cohort 8)Axitinib + Pemetrexed + Cisplatin (Cohort 9)
Plasma Decay Half Life (t1/2) for Axitinib (AG-013736)2.75 ± 2.062.90 ± 1.782.80 ± 1.041.45 ± 0.274.07 ± 2.603.85 ± 1.933.64 ± 2.032.68 ± 1.095.02 ± 3.38
SecondaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Paclitaxel

AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).

Time frame:
0 (pre-dose), 1, 2, 3, 3.25, 3.5, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3; 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 4
Reported as:
Mean · ng*hr/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Paclitaxel
ng*hr/mLAxitinib + Paclitaxel (Cohort 4)Axitinib + Paclitaxel + Carboplatin (Combined Cohort 1, 2, 3)
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Paclitaxel5683.55 ± 1519.4919959.91 ± 5951.86
SecondaryMaximum Observed Plasma Concentration (Cmax) for Paclitaxel
Time frame:
0 (pre-dose), 1, 2, 3, 3.25, 3.5, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3; 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 4
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) for Paclitaxel
ng/mLAxitinib + Paclitaxel (Cohort 4)Axitinib + Paclitaxel + Carboplatin (Combined Cohort 1, 2, 3)
Maximum Observed Plasma Concentration (Cmax) for Paclitaxel3698.33 ± 1198.326105.00 ± 2167.59
SecondaryMinimum Observed Plasma Trough Concentration (Cmin) for Paclitaxel
Time frame:
0 (pre-dose), 1, 2, 3, 3.25, 3.5, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3; 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 4
Reported as:
Mean · ng/mL

No measurements were reported for this outcome.

SecondaryPlasma Clearance (CL) for Paclitaxel

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the plasma.

Time frame:
0 (pre-dose), 1, 2, 3, 3.25, 3.5, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3; 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 4
Reported as:
Mean · L/hr
Plasma Clearance (CL) for Paclitaxel
L/hrAxitinib + Paclitaxel (Cohort 4)Axitinib + Paclitaxel + Carboplatin (Combined Cohort 1, 2, 3)
Plasma Clearance (CL) for Paclitaxel30.48 ± 6.1621.61 ± 9.38
SecondaryPlasma Decay Half Life (t1/2) for Paclitaxel

t1/2 is the time measured for the plasma concentration to decrease by one half.

Time frame:
0 (pre-dose), 1, 2, 3, 3.25, 3.5, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3; 0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 4
Reported as:
Mean · hr
Plasma Decay Half Life (t1/2) for Paclitaxel
hrAxitinib + Paclitaxel (Cohort 4)Axitinib + Paclitaxel + Carboplatin (Combined Cohort 1, 2, 3)
Plasma Decay Half Life (t1/2) for Paclitaxel12.51 ± 1.038.36 ± 2.16
SecondaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Docetaxel

AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).

Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 5
Reported as:
Mean · ng*hr/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Docetaxel
ng*hr/mLAxitinib + Docetaxel (Cohort 5)
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Docetaxel3478.49 ± 870.12
SecondaryMaximum Observed Plasma Concentration (Cmax) for Docetaxel
Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 5
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) for Docetaxel
ng/mLAxitinib + Docetaxel (Cohort 5)
Maximum Observed Plasma Concentration (Cmax) for Docetaxel3130.00 ± 1106.23
SecondaryMinimum Observed Plasma Trough Concentration (Cmin) for Docetaxel
Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 5
Reported as:
Mean · ng/mL

No measurements were reported for this outcome.

SecondaryPlasma Clearance (CL) for Docetaxel

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the plasma.

Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 5
Reported as:
Mean · L/hr
Plasma Clearance (CL) for Docetaxel
L/hrAxitinib + Docetaxel (Cohort 5)
Plasma Clearance (CL) for Docetaxel42.96 ± 6.04
SecondaryPlasma Decay Half Life (t1/2) for Docetaxel

t1/2 is the time measured for the plasma concentration to decrease by one half.

Time frame:
0 (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 30 hr after start of infusion on Day 1 of Cycle 2 for cohort 5
Reported as:
Mean · hr
Plasma Decay Half Life (t1/2) for Docetaxel
hrAxitinib + Docetaxel (Cohort 5)
Plasma Decay Half Life (t1/2) for Docetaxel11.49 ± 0.97
SecondaryArea Under the Curve From Time Zero to Time 24 Hours [AUC (0-24)] for Capecitabine

AUC (0-24) = Area under the plasma concentration versus time curve from time zero (pre-dose) to time 24 hours (0-24).

Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hr post-dose on Day 1 of Cycle 2 for cohort 6 and 7
Reported as:
Mean · ng*hr/mL
Area Under the Curve From Time Zero to Time 24 Hours [AUC (0-24)] for Capecitabine
ng*hr/mLAxitinib + Capecitabine (Cohort 6)Axitinib + Capecitabine (Cohort 7)
Area Under the Curve From Time Zero to Time 24 Hours [AUC (0-24)] for Capecitabine20534.52 ± 3797.6322163.88 ± 16881.96
SecondaryMaximum Observed Plasma Concentration (Cmax) for Capecitabine
Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hr post-dose on Day 1 of Cycle 2 for cohort 6 and 7
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) for Capecitabine
ng/mLAxitinib + Capecitabine (Cohort 6)Axitinib + Capecitabine (Cohort 7)
Maximum Observed Plasma Concentration (Cmax) for Capecitabine10808.00 ± 6173.6210588.38 ± 9954.76
SecondaryMinimum Observed Plasma Trough Concentration (Cmin) for Capecitabine
Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hr post-dose on Day 1 of Cycle 2 for cohort 6 and 7
Reported as:
Mean · ng/mL

No measurements were reported for this outcome.

SecondaryApparent Oral Clearance (CL/F) for Capecitabine

Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes and F is the absolute oral bioavailability. Apparent oral clearance(CL/F) is obtained following oral administration.

Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hr post-dose on Day 1 of Cycle 2 for cohort 6 and 7
Reported as:
Mean · Liter/hr
Apparent Oral Clearance (CL/F) for Capecitabine
Liter/hrAxitinib + Capecitabine (Cohort 6)Axitinib + Capecitabine (Cohort 7)
Apparent Oral Clearance (CL/F) for Capecitabine209.05 ± 24.29314.12 ± 247.27
SecondaryPlasma Decay Half Life (t1/2) for Capecitabine

t1/2 is the time measured for the plasma concentration to decrease by one half.

Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hr post-dose on Day 1 of Cycle 2 for cohort 6 and 7
Reported as:
Mean · hr
Plasma Decay Half Life (t1/2) for Capecitabine
hrAxitinib + Capecitabine (Cohort 6)Axitinib + Capecitabine (Cohort 7)
Plasma Decay Half Life (t1/2) for Capecitabine0.85 ± 0.901.44 ± 3.05
SecondaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Gemcitabine

AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).

Time frame:
0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4 hr after start of infusion on Day 1 of Cycle 2 for cohort 8
Reported as:
Mean · ng*hr/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Gemcitabine
ng*hr/mLAxitinib + Gemcitabine + Cisplatin (Cohort 8)
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Gemcitabine10991.16 ± 3099.28
SecondaryMaximum Observed Plasma Concentration (Cmax) for Gemcitabine
Time frame:
0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4 hr after start of infusion on Day 1 of Cycle 2 for cohort 8
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) for Gemcitabine
ng/mLAxitinib + Gemcitabine + Cisplatin (Cohort 8)
Maximum Observed Plasma Concentration (Cmax) for Gemcitabine20635.29 ± 10656.86
SecondaryMinimum Observed Plasma Trough Concentration (Cmin) for Gemcitabine
Time frame:
0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4 hr after start of infusion on Day 1 of Cycle 2 for cohort 8
Reported as:
Mean · ng/mL

No measurements were reported for this outcome.

SecondaryPlasma Clearance (CL) for Gemcitabine

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the plasma.

Time frame:
0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4 hr after start of infusion on Day 1 of Cycle 2 for cohort 8
Reported as:
Mean · L/hr
Plasma Clearance (CL) for Gemcitabine
L/hrAxitinib + Gemcitabine + Cisplatin (Cohort 8)
Plasma Clearance (CL) for Gemcitabine224.36 ± 74.45
SecondaryPlasma Decay Half Life (t1/2) for Gemcitabine

t1/2 is the time measured for the plasma concentration to decrease by one half.

Time frame:
0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4 hr after start of infusion on Day 1 of Cycle 2 for cohort 8
Reported as:
Mean · hr
Plasma Decay Half Life (t1/2) for Gemcitabine
hrAxitinib + Gemcitabine + Cisplatin (Cohort 8)
Plasma Decay Half Life (t1/2) for Gemcitabine0.29 ± 0.07
SecondaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Carboplatin

AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).

Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 5 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3
Reported as:
Mean · ng*hr/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Carboplatin
ng*hr/mLAxitinib + Paclitaxel + Carboplatin (Combined Cohort 1, 2, 3)
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Carboplatin55580.26 ± 9689.44
SecondaryMaximum Observed Plasma Concentration (Cmax) for Carboplatin
Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 5 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) for Carboplatin
ng/mLAxitinib + Paclitaxel + Carboplatin (Combined Cohort 1, 2, 3)
Maximum Observed Plasma Concentration (Cmax) for Carboplatin23383.33 ± 7170.75
SecondaryMinimum Observed Plasma Trough Concentration (Cmin) for Carboplatin
Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 5 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3
Reported as:
Mean · ng/mL

No measurements were reported for this outcome.

SecondaryPlasma Clearance (CL) for Carboplatin

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the plasma.

Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 5 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3
Reported as:
Mean · L/hr
Plasma Clearance (CL) for Carboplatin
L/hrAxitinib + Paclitaxel + Carboplatin (Combined Cohort 1, 2, 3)
Plasma Clearance (CL) for Carboplatin12.57 ± 3.99
SecondaryPlasma Decay Half Life (t1/2) for Carboplatin

t1/2 is the time measured for the plasma concentration to decrease by one half.

Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 5 hr after start of infusion on Day 1 of Cycle 2 for cohort 1-3
Reported as:
Mean · hr
Plasma Decay Half Life (t1/2) for Carboplatin
hrAxitinib + Paclitaxel + Carboplatin (Combined Cohort 1, 2, 3)
Plasma Decay Half Life (t1/2) for Carboplatin2.62 ± 0.55
SecondaryArea Under the Curve From Time Zero to Time 8 Hours [AUC (0-8)] for Cisplatin

AUC (0-8) = Area under the plasma concentration versus time curve from time zero (pre-dose) to time 8 hours (0-8).

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 3, 5, 7 hr after start of infusion on Day 1 of Cycle 2 for cohort 8 and 9
Reported as:
Mean · ng*hr/mL
Area Under the Curve From Time Zero to Time 8 Hours [AUC (0-8)] for Cisplatin
ng*hr/mLAxitinib + Gemcitabine + Cisplatin (Cohort 8)Axitinib + Pemetrexed + Cisplatin (Cohort 9)
Area Under the Curve From Time Zero to Time 8 Hours [AUC (0-8)] for Cisplatin2932.43 ± 929.692703.92 ± 688.68
SecondaryMaximum Observed Plasma Concentration (Cmax) for Cisplatin
Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 3, 5, 7 hr after start of infusion on Day 1 of Cycle 2 for cohort 8 and 9
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) for Cisplatin
ng/mLAxitinib + Gemcitabine + Cisplatin (Cohort 8)Axitinib + Pemetrexed + Cisplatin (Cohort 9)
Maximum Observed Plasma Concentration (Cmax) for Cisplatin1680.54 ± 628.631176.00 ± 295.29
SecondaryMinimum Observed Plasma Trough Concentration (Cmin) for Cisplatin
Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 3, 5, 7 hr after start of infusion on Day 1 of Cycle 2 for cohort 8 and 9
Reported as:
Mean · ng/mL

No measurements were reported for this outcome.

SecondaryPlasma Clearance (CL) for Cisplatin

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the plasma.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 3, 5, 7 hr after start of infusion on Day 1 of Cycle 2 for cohort 8 and 9
Reported as:
Mean · L/hr
Plasma Clearance (CL) for Cisplatin
L/hrAxitinib + Gemcitabine + Cisplatin (Cohort 8)Axitinib + Pemetrexed + Cisplatin (Cohort 9)
Plasma Clearance (CL) for Cisplatin46.31 ± 14.5746.80 ± 14.92
SecondaryPlasma Decay Half Life (t1/2) for Cisplatin

t1/2 is the time measured for the plasma concentration to decrease by one half.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 3, 5, 7 hr after start of infusion on Day 1 of Cycle 2 for cohort 8 and 9
Reported as:
Mean · hr
Plasma Decay Half Life (t1/2) for Cisplatin
hrAxitinib + Gemcitabine + Cisplatin (Cohort 8)Axitinib + Pemetrexed + Cisplatin (Cohort 9)
Plasma Decay Half Life (t1/2) for Cisplatin2.61 ± 1.273.91 ± 1.59
SecondaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Pemetrexed

AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).

Time frame:
0 (pre-dose), 10 minutes (end of infusion), 0.5, 1, 1.5, 2, 4, 6, 8 hr after end of infusion on Day 1 of Cycle 2 for cohort 9
Reported as:
Mean · ng*hr/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Pemetrexed
ng*hr/mLAxitinib + Pemetrexed + Cisplatin (Cohort 9)
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Pemetrexed133032.97 ± 40176.65
SecondaryMaximum Observed Plasma Concentration (Cmax) for Pemetrexed
Time frame:
0 (pre-dose), 10 minutes (end of infusion), 0.5, 1, 1.5, 2, 4, 6, 8 hr after end of infusion on Day 1 of Cycle 2 for cohort 9
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) for Pemetrexed
ng/mLAxitinib + Pemetrexed + Cisplatin (Cohort 9)
Maximum Observed Plasma Concentration (Cmax) for Pemetrexed83925.00 ± 35820.05
SecondaryMinimum Observed Plasma Trough Concentration (Cmin) for Pemetrexed
Time frame:
0 (pre-dose), 10 minutes (end of infusion), 0.5, 1, 1.5, 2, 4, 6, 8 hr after end of infusion on Day 1 of Cycle 2 for cohort 9
Reported as:
Mean · ng/mL

No measurements were reported for this outcome.

SecondaryPlasma Clearance (CL) for Pemetrexed

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the plasma.

Time frame:
0 (pre-dose), 10 minutes (end of infusion), 0.5, 1, 1.5, 2, 4, 6, 8 hr after end of infusion on Day 1 of Cycle 2 for cohort 9
Reported as:
Mean · L/hr
Plasma Clearance (CL) for Pemetrexed
L/hrAxitinib + Pemetrexed + Cisplatin (Cohort 9)
Plasma Clearance (CL) for Pemetrexed7.26 ± 2.08
SecondaryPlasma Decay Half Life (t1/2) for Pemetrexed

t1/2 is the time measured for the plasma concentration to decrease by one half.

Time frame:
0 (pre-dose), 10 minutes (end of infusion), 0.5, 1, 1.5, 2, 4, 6, 8 hr after end of infusion on Day 1 of Cycle 2 for cohort 9
Reported as:
Mean · hr
Plasma Decay Half Life (t1/2) for Pemetrexed
hrAxitinib + Pemetrexed + Cisplatin (Cohort 9)
Plasma Decay Half Life (t1/2) for Pemetrexed2.77 ± 1.80
SecondaryPercentage of Participants With Objective Response

Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0. Confirmed response are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

Time frame:
Baseline and thereafter every 2 cycles up to disease progression or discontinuation from study or up to 155 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Objective Response
Percentage of ParticipantsAxitinib + Paclitaxel + Carboplatin (Cohort 1)Axitinib + Paclitaxel + Carboplatin (Cohort 2)Axitinib + Paclitaxel + Carboplatin (Cohort 3)Axitinib + Paclitaxel (Cohort 4)Axitinib + Docetaxel (Cohort 5)Axitinib + Capecitabine (Cohort 6)Axitinib + Capecitabine (Cohort 7)Axitinib + Gemcitabine + Cisplatin (Cohort 8)Axitinib + Pemetrexed + Cisplatin (Cohort 9)
Percentage of Participants With Objective Response100.0035.066.750.011.111.823.80

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Axitinib + Paclitaxel + Carboplatin (Cohort 1)—2/3 (66.7%)3/3 (100%)
Axitinib + Paclitaxel + Carboplatin (Cohort 2)—2/5 (40%)5/5 (100%)
Axitinib + Paclitaxel + Carboplatin (Cohort 3)—11/20 (55%)20/20 (100%)
Axitinib + Paclitaxel (Cohort 4)—2/7 (28.6%)7/7 (100%)
Axitinib + Docetaxel + Carboplatin (Cohort 4a)—1/1 (100%)1/1 (100%)
Axitinib + Docetaxel (Cohort 5)—4/7 (57.1%)7/7 (100%)
Axitinib + Capecitabine (Cohort 6)—6/9 (66.7%)9/9 (100%)
Axitinib + Capecitabine (Cohort 7)—9/19 (47.4%)19/19 (100%)
Axitinib + Gemcitabine + Cisplatin (Cohort 8)—13/21 (61.9%)21/21 (100%)
Axitinib + Pemetrexed + Cisplatin (Cohort 9)—4/6 (66.7%)6/6 (100%)
Most frequent serious events
Showing 10 of 80
Most frequent serious events
EventAxitinib + Paclitaxel + Carboplatin (Cohort 1)Axitinib + Paclitaxel + Carboplatin (Cohort 2)Axitinib + Paclitaxel + Carboplatin (Cohort 3)Axitinib + Paclitaxel (Cohort 4)Axitinib + Docetaxel + Carboplatin (Cohort 4a)Axitinib + Docetaxel (Cohort 5)Axitinib + Capecitabine (Cohort 6)Axitinib + Capecitabine (Cohort 7)Axitinib + Gemcitabine + Cisplatin (Cohort 8)Axitinib + Pemetrexed + Cisplatin (Cohort 9)
GranulocytopeniaBlood and lymphatic system disorders0/30/50/200/71/10/70/90/190/210/6
DiarrhoeaGastrointestinal disorders0/30/50/200/71/11/70/91/190/210/6
NauseaGastrointestinal disorders0/30/50/200/71/11/70/91/192/210/6
VomitingGastrointestinal disorders0/30/51/200/71/10/70/91/191/210/6
AstheniaGeneral disorders0/30/51/200/71/11/70/90/190/210/6
FatigueGeneral disorders0/31/50/200/71/11/70/91/191/210/6
DiverticulitisInfections and infestations0/30/50/200/71/10/70/90/190/210/6
DehydrationMetabolism and nutrition disorders0/30/51/201/71/11/71/91/192/210/6
Peripheral sensory neuropathyNervous system disorders0/30/50/200/71/10/70/90/190/210/6
Renal failure acuteRenal and urinary disorders0/30/50/200/71/10/70/91/191/210/6
Most frequent other events
Showing 10 of 290
Most frequent other events
EventAxitinib + Paclitaxel + Carboplatin (Cohort 1)Axitinib + Paclitaxel + Carboplatin (Cohort 2)Axitinib + Paclitaxel + Carboplatin (Cohort 3)Axitinib + Paclitaxel (Cohort 4)Axitinib + Docetaxel + Carboplatin (Cohort 4a)Axitinib + Docetaxel (Cohort 5)Axitinib + Capecitabine (Cohort 6)Axitinib + Capecitabine (Cohort 7)Axitinib + Gemcitabine + Cisplatin (Cohort 8)Axitinib + Pemetrexed + Cisplatin (Cohort 9)
NeutropeniaBlood and lymphatic system disorders3/33/57/201/70/12/72/92/1911/210/6
Abdominal painGastrointestinal disorders0/31/52/202/71/13/73/93/196/211/6
DiarrhoeaGastrointestinal disorders3/33/57/205/71/14/74/914/198/211/6
NauseaGastrointestinal disorders3/35/55/205/70/14/75/912/1915/212/6
AstheniaGeneral disorders2/32/53/200/71/10/72/91/192/211/6
FatigueGeneral disorders3/34/59/207/70/15/77/913/1916/212/6
Oedema peripheralGeneral disorders0/31/51/201/71/11/72/91/192/210/6
Decreased appetiteMetabolism and nutrition disorders2/34/59/203/71/13/73/911/1911/212/6
MyalgiaMusculoskeletal and connective tissue disorders0/32/56/202/71/11/71/93/190/210/6
DizzinessNervous system disorders2/32/53/202/71/11/72/94/196/210/6

Baseline characteristics

Age Continuous
Age Continuous(years)Axitinib + Paclitaxel + Carboplatin (Cohort 1)Axitinib + Paclitaxel + Carboplatin (Cohort 2)Axitinib + Paclitaxel + Carboplatin (Cohort 3)Axitinib + Paclitaxel (Cohort 4)Axitinib + Docetaxel + Carboplatin (Cohort 4a)Axitinib + Docetaxel (Cohort 5)Axitinib + Capecitabine (Cohort 6)Axitinib + Capecitabine (Cohort 7)Axitinib + Gemcitabine + Cisplatin (Cohort 8)Axitinib + Pemetrexed + Cisplatin (Cohort 9)Total
Mean61 ± 11.462 ± 16.659.5 ± 10.660.7 ± 10.264 ± NA63.4 ± 11.960.4 ± 12.453.4 ± 10.654 ± 10.358.8 ± 9.057.8 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Axitinib + Paclitaxel + Carboplatin (Cohort 1)Axitinib + Paclitaxel + Carboplatin (Cohort 2)Axitinib + Paclitaxel + Carboplatin (Cohort 3)Axitinib + Paclitaxel (Cohort 4)Axitinib + Docetaxel + Carboplatin (Cohort 4a)Axitinib + Docetaxel (Cohort 5)Axitinib + Capecitabine (Cohort 6)Axitinib + Capecitabine (Cohort 7)Axitinib + Gemcitabine + Cisplatin (Cohort 8)Axitinib + Pemetrexed + Cisplatin (Cohort 9)Total
Female22331551112347
Male1317402489351
08

Study locations

13 sites
  • Pfizer Investigational Site
    Augusta, Georgia 30909, United States
  • Pfizer Investigational Site
    Augusta, Georgia 30912, United States
  • Pfizer Investigational Site
    Harvey, Illinois 60426-4265, United States
  • Pfizer Investigational Site
    Harvey, Illinois 60426, United States
  • Pfizer Investigational Site
    Tinley Park, Illinois 60477, United States
  • Pfizer Investigational Site
    Hobart, Indiana 46342, United States
  • Pfizer Investigational Site
    Munster, Indiana 46321, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania 19111, United States
  • Pfizer Investigational Site
    Houston, Texas 77030-4009, United States
  • Pfizer Investigational Site
    Kennewick, Washington 99336, United States
  • Pfizer Investigational Site
    Warszawa, 02-781, Poland
  • Pfizer Investigational Site
    Barcelona, 08003, Spain
  • Pfizer Investigational Site
    Madrid, 28046, Spain
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of Aug 2009 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2007
First posted
Apr 2, 2007
Start
Dec 2005
Primary completionActual
Aug 2009
CompletionActual
Apr 2011
Results first posted
Mar 27, 2012
Last update
Apr 4, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00454649
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 2, 2007
Start date
Dec 2005
Primary completion
Aug 2009
Completion
Apr 2011
Results posted
Mar 27, 2012
Last update
Apr 4, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Axitinib · Paclitaxel · Carboplatin · Docetaxel · Capecitabine · Gemcitabine · Cisplatin · Pemetrexed

Start the discussion